Document Detail

Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study.
MedLine Citation:
PMID:  12236319     Owner:  NLM     Status:  MEDLINE    
The Chiba Lipid Intervention Program (CLIP) Study was designed to clarify the prognosis of Japanese hypercholesterolemic patients taking pravastatin for 5 years. Hypercholesterolemic patients (n = 2,529) with a total cholesterol level > or = 220 mg/dl and without histories of ischemic coronary heart disease and/or cerebral infarction were administered pravastatin (10-20 mg/day). Among them, 2,131 took pravastatin fully (Pravastatin-continued group), and 398 discontinued the treatment (Discontinued group). The baseline total cholesterol level was 264.3 +/- 34.7 mg/dl (mean +/- standard deviation). The mean reduction rates of total cholesterol and low-density lipoprotein (LDL) cholesterol were 18.0% and 27.2%, respectively. Mild and moderate adverse events occurred in 86 cases (3.6%). Serious adverse events were not observed. Death rates of the pravastatin-continued group and of the discontinued group were 2.6 and 16.0/1,000 persons/year, respectively. Cardiac events (fatal and nonfatal myocardial infarction, cardiac death, angina pectoris) in all, occurred in 35 patients (incidence rate = 2.77/1,000 persons/year). In the pravastatin continued group, 9 causes of fatal and nonfatal myocardial infarction occurred (0.84/1,000 persons/year), whereas in the discontinued group, 4 cases occurred (2.06/1,000 persons/ year). The risk ratio for cardiac events was correlated with the number of risks. In the low-risk group (< or = 1 risk), decreased rates of LDL-cholesterol were less in the cardiac event group than the non-cardiac event group (LDL-cholesterol; 16% vs 25%, p = 0.04). These results suggested the following; 1) Pravastatin maintained a cholesterol lowering effect long-term without serious complications. 2) Pravastatin administration might reduce the mortality rate and myocardial infarction. 3) The combination of multiple risks is a strong factor for a cardiac event in addition to hypercholesterolemia.
Yasushi Saito; Kohji Shirai; Norihiro Sasaki; Masaki Shinomiya; Sho Yoshida;
Related Documents :
15771919 - Electrocardiographic events and cholesterol reduction with pravastatin in patients with...
12182229 - Hmg-co a reductase inhibitors in the treatment of cardiovascular diseases: stabilizatio...
17910519 - Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
2205799 - Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart d...
11231429 - Design and rationale of the arbiter trial (arterial biology for the investigation of th...
18417069 - Adjunctive interventions in myocardial infarction: the role of statin therapy.
15546369 - Electromechanical coupling, uncoupling, and ventricular function in patients with bundl...
17584679 - Defibrillation threshold testing and neurologic outcome.
313189 - Perioperative myocardial infarction associated with coronary artery bypass graft surger...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of atherosclerosis and thrombosis     Volume:  9     ISSN:  1340-3478     ISO Abbreviation:  J. Atheroscler. Thromb.     Publication Date:  2002  
Date Detail:
Created Date:  2002-09-18     Completed Date:  2003-03-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9506298     Medline TA:  J Atheroscler Thromb     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  99-108     Citation Subset:  IM    
Second Department of Internal Medicine, School of Medicine, Chiba University, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angina Pectoris / blood,  mortality
Anticholesteremic Agents / administration & dosage*,  adverse effects
Arrhythmias, Cardiac / blood,  mortality
Cause of Death
Follow-Up Studies
Heart Failure / blood,  mortality
Hypercholesterolemia / blood,  drug therapy*,  mortality*
Lipids / blood
Middle Aged
Myocardial Infarction / blood,  mortality
Pravastatin / administration & dosage*,  adverse effects
Prospective Studies
Risk Factors
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Lipids; 81093-37-0/Pravastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunohistochemical localization and mRNA expression of apolipoprotein A-I in rat spinal cord.
Next Document:  The functional significance of ERP effects during mental rotation.